Seikagaku Corp (4548.T)
23 Mar 2018
BRIEF-Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan
* Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation
* Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation.
* Says it signed collaborative research contract with SEIKAGAKU CORPORATION